Professor Bob Chaudhuri

Qualifications: PhD

Research Interests

Cell Division Cycle, Protein Kinases, Apoptosis, Drug Metabolism, Molecular Toxicology.

Recent Publications

1. Mahale S. and Chaudhuri B. CRC Press (Editors Smith PJ, Yue EW)CRC Enzyme Inhibitor Series.Inhibitors of cyclin-dependent kinases as anti-tumor agents. 2007. Development of Cdk inhibitors as anti-cancer agents: from rational design to Cdk4-specific inhibition. 121-142.
2. García MD, Wilson AJ, Emmerson DP, Jenkins PR, Mahale S, Chaudhuri B. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors. Org Biomol Chem. 2006 Dec 21;4(24):4478-84.
3. Mahale S, Aubry C, Jenkins PR, Maréchal JD, Sutcliffe MJ,Chaudhuri B. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. Bioorg Chem. 2006 Oct;34(5):287-97.
4. Mahale S, Aubry C, James Wilson A, Jenkins PR, Maréchal JD, Sutcliffe MJ, Chaudhuri B. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.Bioorg Med ChemLett. 2006 Aug 15;16(16):4272-8.
5. Aubry C, Jenkins PR, Mahale S, Chaudhuri B, Marechal JD, Sutcliffe MJ. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.Chem Commun. (Camb). 2004 Aug 8;(15):1696-7. Epub 2004 Jun 25.
6. Mukku VJ, Edrada RA, Schmitz FJ, Shanks MK, Chaudhuri B, Fabbro D. New sesquiterpene quinols from a Micronesian sponge, Aka sp. J Nat Prod. 2003 May;66(5):686-9.
7. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98.
8. Schoepfer J, Fretz H, Chaudhuri B, Muller L, Seeber E, Meijer L, Lozach O, Vangrevelinghe E, Furet P. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J Med Chem. 2002 Apr 25;45(9):1741-7.
9. Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst. 2001 Mar 21;93(6):436-46.

Projects

• Development of a less toxic analogue of fascaplysin as a novel therapeutic agent for the treatment of cancer: Cancer Research-UK.
• Identifying tissue-specific apoptosis inhibitory proteins using a cell-based functional genomics screen: Protherics Plc.
• Development of an integrated system for the functional expression of highly active cytochrome P450 enzymes: The Edith Murphy Foundation.

Esteem/Professional Contribution

• Member of the Scientific Advisory Board of Nicholas Piramal Research Center http://www.nicholaspiramal.com/rnd.htm
• Consultant to Morvus Technology http://www.morvus.com/